<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02570399</url>
  </required_header>
  <id_info>
    <org_study_id>1388</org_study_id>
    <nct_id>NCT02570399</nct_id>
  </id_info>
  <brief_title>High Dose SBRT for Abdominal-Pelvic Lymph Nodal Lesions in Oligometastatic Patients</brief_title>
  <official_title>Feasibility Study of High Dose Stereotactic Body Radiation Therapy (SBRT) for Lymph Nodal Lesions in Oligometastatic Patients for Genito-urinary, Gastro-intestinal and Gynaecological Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicentric, phase II and feasibility study aimed to address early
      and late side effects of hypofractionated ablative radiotherapy for oligometastatic patients
      with lymph node metastases for genito-urinary, gastro-intestinal and gynaecological cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this prospective, multicentric, phase II study is to determine the feasibility
      of Stereotactic Body Radiation Therapy in stage IV selected oligometastatic patients, by
      looking at acute and late toxicity. Investigators also want to verify what is the impact of
      local control in irradiated metastatic foci in the context of the systemic disease, how local
      control can affect disease free survival and overall survival, and moreover quality of life
      of patients treated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility in terms of toxicity related to radiation therapy</measure>
    <time_frame>2 months</time_frame>
    <description>Evaluation of acute and late toxicity performed during and after radiation therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumour response to local radiation therapy (RECIST criteria)</measure>
    <time_frame>2 months</time_frame>
    <description>Evaluation of tumour response to local radiation therapy by means of imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in the oligometastatic patients</measure>
    <time_frame>2 months</time_frame>
    <description>Statistical evaluation of how local control of the metastatic disease can affect overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival in the oligometastatic patients</measure>
    <time_frame>2 months</time_frame>
    <description>Statistical evaluation of how local control of the metastatic disease can affect disease free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire of treated patients</measure>
    <time_frame>2 months</time_frame>
    <description>Evaluation of quality of life of patients during and after radiation therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Lymph Node Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Lymph nodal metastatic lesions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oligometastatic patients with abdominal-pelvic lymph nodes</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Oligometastatic patients with abdominal-pelvic lymph nodes</intervention_name>
    <description>Hypofractionated ablative radiation therapy for oligometastatic patients with lymph node metastases</description>
    <arm_group_label>Lymph nodal metastatic lesions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  WHO performance status ≤ 2

          -  Histologically-proven of primary cancer disease

          -  M1 stage with primary cancer site radically treated with complete response/resection
             or stable. No other site of disease in progression (a maximum of 3 lymph node sites of
             disease to treat)

          -  Diameter ≤ 5 cm

          -  Abdomen/pelvic site

          -  Informed consent.

        Exclusion Criteria:

          -  Patients were required to have not brain metastases or bone metastases.

          -  Patients with a life expectancy of &gt;3 months.

          -  Any serious disease contraindicated radiation therapy

          -  Other coexisting malignancies, uncontrolled intercurrent illness, active infectious
             processes, and exudative, bloody, or cytologically malignant effusions excluded
             patients from the trial. Additionally, patients were excluded from the trial if they
             were receiving any systemic chemotherapy during radiotherapy, although hormonal
             therapy was allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ciro Franzese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ciro Franzese, MD</last_name>
    <phone>+39028224</phone>
    <phone_ext>7454</phone_ext>
    <email>ciro.franzese@cancercenter.humanitas.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clerici Elena, MD</last_name>
    <phone>+39028224</phone>
    <phone_ext>7310</phone_ext>
    <email>elena.clerici@humanitas.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciro Franzese, MD</last_name>
      <phone>+39028224</phone>
      <phone_ext>7454</phone_ext>
      <email>ciro.franzese@cancercenter.humanitas.it</email>
    </contact>
    <contact_backup>
      <last_name>Elena Clerici, MD</last_name>
      <phone>+39028224</phone>
      <phone_ext>7310</phone_ext>
      <email>elena.clerici@cancercenter.humanitas.it</email>
    </contact_backup>
    <investigator>
      <last_name>Ciro Franzese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Clerici, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2015</study_first_submitted>
  <study_first_submitted_qc>October 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2015</study_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Michele Tedeschi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

